Welcome back to the journal review. This is the October twenty twenty-six issue of the Journal of the American Academy of Dermatology, and we've got four pieces worth your time this month — a surgical technique brief report, a natural-language-processing methods study, a public-health letter from the Rockies, and a genetics-and-outcomes cohort study out of the TriNetX network. Let's get into it.

First up is a brief report: barbed suture-assisted high-tension cutaneous closure, a retrospective case series of four hundred ninety-three surgical defects from a single dermatologic surgeon. You all know the clinical problem here — a defect where extensive undermining is either undesirable, because of bleeding risk, or just won't buy you enough mobility, particularly in thin, photodamaged, atrophic skin on the upper back, shoulder, or sternal chest. The pitch for barbed suture is that it distributes tension continuously along the running closure rather than concentrating it at discrete knot points, theoretically giving you progressive, distributed wound-edge approximation instead of relying on aggressive undermining or reaching for a graft.

Methodologically this is about as straightforward as it gets — a retrospective, single-surgeon case series, no control arm, no formal statistical testing, which is entirely appropriate for what this is: a descriptive brief report meant to characterize a technique and a case mix, not to prove causality or superiority. High tension was defined clinically rather than by any objective metric — expected need for extensive undermining, risk of tearing with simple linear closure, or defects in those classic high-risk anatomic zones. The workhorse product was a three-0 or four-0 absorbable monofilament, Quill Monoderm, a copolymer of glycolide and caprolactone, with occasional use of a longer-lasting barbed PDO suture, V-Loc, when they wanted extended support. Technique was a locking loop followed by running deep dermal and subcutaneous plication, building additional deep layers as needed to get dermis-to-dermis contact under minimal tension before standard superficial closure.

On the numbers: mean defect area was about eight square centimeters, with a fairly wide spread — standard deviation pushing ten — and a range stretching from well under one square centimeter up to the mid-nineties, so this covers everything from modest to quite large defects. The headline safety finding is reassuring: most wounds healed without major complication, and critically, no dehiscence was documented across this cohort. The one adverse signal worth flagging for your own practice is unexpected postoperative pain, which clustered after aggressive deep plication in nerve-sensitive areas like the postauricular region — a reminder that the self-anchoring tension of barbed suture can translate into more discomfort than you'd expect from a standard running closure in those zones. They also noted suture-spitting with the longer-absorbing PDO product, which pushed them toward favoring the shorter-absorbing Monoderm, though they're upfront that they didn't systematically track spitting rates by product, so that's an impression, not a quantified finding.

Limitations are exactly what you'd expect from this design — selective case use introduces real selection bias since we don't know how these four hundred ninety-three defects were chosen relative to the surgeon's overall caseload, there's no comparator closure technique, and pain and long-term cosmetic outcome were not assessed in any standardized way. So practically: this is interesting and consistent with prior literature on barbed suture mechanics, but it's not practice-changing data — it's a reassurance-and-reminder piece. If you're already using barbed suture-assisted closure for difficult, high-tension, low-undermining-tolerance defects, this supports continuing to do so, with two concrete pearls — favor shorter-absorbing monofilament over longer-lasting PDO to reduce spitting risk, and be more conservative with deep plication near named sensory nerves, counseling patients up front about possible postoperative discomfort.

Next, a genuinely methods-forward brief report: a comparison of natural language processing versus ICD coding — International Classification of Diseases coding — for skin cancer subtype identification from pathology reports. The gap here is one you've probably felt yourself if you've ever tried to do outcomes research using administrative data: ICD codes are notoriously unreliable for skin cancer surveillance because they capture provisional, rule-out, or historical diagnoses rather than confirmed histology. The authors cite prior work showing essentially poor correlation, around point two two, between ICD-based estimates and actual histologically confirmed skin cancer counts. Manual chart review is the gold standard but obviously doesn't scale.

So the design: a retrospective pull from Mohs surgery case logs at Baylor College of Medicine spanning 2007 to 2024. They started with all Mohs cases from 2020 to 2021, randomly sampled one hundred eighty patients, and traced those patients' full pathology history, landing on a final analytic set of close to twenty-eight hundred lesions across twelve hundred forty-one pathology reports from one hundred fifty-two patients. The tool was Bio-ClinicalBERT, a transformer-based language model pretrained on biomedical text and then fine-tuned specifically to predict the manually-confirmed diagnosis from the free-text pathology report, classified into four buckets — squamous cell carcinoma, squamous cell carcinoma in situ, basal cell carcinoma, and an "other" category.

Here's the methodology worth dwelling on: they validated using nested five-fold cross-validation. In plain terms, cross-validation means you split your data into chunks, train the model on most of them, and test it on the held-out chunk, then rotate which chunk is held out — this protects against a model simply memorizing its training data and gives you a more honest estimate of how it'll perform on patients it's never seen. "Nested" cross-validation adds an inner loop for tuning the model's own settings, so that the data used to pick the best model configuration is kept separate from the data used to judge final performance — that separation matters because without it, your accuracy estimate is optimistically biased. They then benchmarked three approaches against each other: the NLP model, raw ICD coding, and manual chart review as the reference standard. For agreement, they leaned on Cohen's kappa, which is worth understanding because it's a metric you'll see throughout diagnostic-accuracy literature — it's not just raw percent agreement, it corrects for the agreement you'd expect by chance alone. A kappa near zero means your method is doing no better than chance, while a kappa above about zero point eight is considered near-perfect agreement.

The results are about as clean a win for NLP as you'll see. Overall accuracy was around ninety-eight percent, with lesion-level error against manual review under one percent across every subtype. ICD-based estimates, by contrast, were wildly off — deviations of roughly seventy-six percent for squamous cell carcinoma counts and over one hundred percent for basal cell carcinoma, meaning ICD codes were essentially unreliable for case-counting. At the patient level, NLP hit about ninety-seven percent accuracy and a kappa in the low nineties, functionally indistinguishable from manual review, while ICD coding's kappa hovered around point five — moderate at best — driven by low precision despite deceptively preserved recall, meaning ICD coding casts a wide net but pulls in a lot of false positives.

The authors are appropriately modest in their conclusions: single-institution design limits generalizability, and they flag that future validation needs multi-institutional data before anyone builds a national surveillance pipeline on this. But the practical takeaway for you is real, even if it's not something you'll change at the bedside tomorrow — if you're involved in any registry work, quality improvement, or retrospective outcomes research drawing on your own pathology archive, this is a strong signal that ICD-based case ascertainment for keratinocyte carcinoma is simply not trustworthy, and that a fine-tuned language model applied directly to your pathology text is a far more defensible way to build a research cohort without drowning in manual chart review.

Now a shorter piece — a letter to the editor out of Colorado, covering a public health intervention rather than a controlled study, so there's no formal methods or limitations scaffolding to walk through, just a descriptive program evaluation. A medical-student-led, grant-funded initiative installed nineteen free sunscreen dispensers across seven Colorado state parks over one season, chosen for operational feasibility given the well-established elevated ultraviolet exposure at altitude. The evaluation here was simple: a descriptive survey of the park rangers responsible for maintaining these dispensers, all seven of whom responded.

The numbers are more about program feasibility than clinical outcome, but they're worth knowing if you're ever asked to support or advise a similar initiative. An estimated four and a half million visitors passed through these parks during the study window. Based on typical refill patterns and an estimated six hundred seventy applications per bottle, the dispensers are estimated to have provided somewhere between roughly twelve and a half thousand and twenty-five thousand sunscreen applications over the season. Ranger sentiment was strongly favorable — five of seven rated the impact very positive, the rest somewhat positive, and all seven planned to reinstall for the following season. Reported operational hiccups were minor and fixable: unclear installation instructions, leakage in high heat, and suboptimal placement affecting visibility.

There's no pretense of rigor beyond what this is — a small, non-comparative sample of rangers rather than visitor-level behavioral data, with real potential for social desirability bias, and refill frequency used as a rough proxy for actual use rather than anything directly measured. The authors are transparent about all of that. The practical relevance for a dermatologic oncologist is less about changing your clinic practice and more about advocacy — this is a low-cost, well-received, logistically simple model, on the order of under a hundred dollars per liter of recurring sunscreen supply, that you could reasonably point to if you're involved in local public health or outdoor-recreation sun-safety efforts. It's a feasibility signal, not an efficacy trial — worth citing in an advocacy conversation, not something that changes management.

Last, and probably the most clinically provocative piece this month: a retrospective cohort study using the TriNetX federated database asking whether genetic predisposition to malignancy changes survival outcomes in cutaneous melanoma. The background here builds on prior work from essentially the same group showing that germline pathogenic variants are identifiable in something like ten to sixteen percent of melanoma patients — a substantial minority — but whether that predisposition translates into better or worse prognosis has been unclear.

Design-wise, they used ICD-10 code C-43 to define a melanoma cohort, and then used the ICD-10 code Z15.0, genetic susceptibility to malignant neoplasm, as a surrogate marker for a co-diagnosis of germline cancer predisposition — worth flagging immediately as a methodological weak point, since that's a coding-based proxy for a genetic status, not confirmed germline testing, and codes can be inconsistently applied. To handle the obvious confounding — patients flagged with a genetic-susceptibility code are likely different from the general melanoma population in ways beyond the mutation itself, things like age, family history, surveillance intensity, comorbidities — they used propensity score matching. It's worth taking a moment on this technique because you'll see it constantly in database studies like this one. Propensity score matching takes all your measured confounders and compresses them into a single number for each patient — the estimated probability of being in the "exposed" group, here genetic susceptibility, given their baseline characteristics. You then pair patients from the two groups who have similar propensity scores, effectively constructing a pseudo-randomized comparison from observational data. It's the tool of choice here specifically because you obviously can't randomize patients to "have" or "not have" a germline predisposition — matching is the next best thing for isolating the variable of interest from the confounders you can measure. The authors used a standard threshold, a standardized mean difference under point one, to confirm their matched groups were well-balanced across baseline characteristics.

Scale-wise, this is a big database pull — over two hundred eighty-seven thousand melanoma patients without the genetic-susceptibility code, versus about twenty-four hundred with it. After matching, they ended up with close to twenty-three hundred patients in each arm. Survival was assessed with Kaplan-Meier curves, the standard way to visualize time-to-event data while properly accounting for patients who are lost to follow-up partway through — rather than just comparing raw proportions dead at a fixed time point, it tracks the probability of survival continuously as the risk set shrinks. The comparison between curves was then summarized with a hazard ratio, which tells you the relative instantaneous risk of death at any given moment between the two groups across the whole follow-up period, rather than just at one snapshot in time.

And the finding was clear and statistically significant: patients without genetic susceptibility to malignancy had meaningfully worse five-year survival than those with it, with a hazard ratio of about one point four — in other words, roughly a forty percent higher relative risk of death in the group without the genetic-susceptibility flag — and the confidence interval stayed well above one, so this isn't a fragile or marginal result. That's a counterintuitive direction if you're expecting "genetic predisposition" to mean "worse disease," and the authors offer a few plausible explanations rather than overclaiming a mechanism. One is biologic, drawing on their own prior work showing that germline-positive melanoma patients have lower levels of a specific myeloid-derived suppressor cell population that's otherwise a biomarker of poor prognosis in advanced disease. Another is more mundane but probably just as important — ascertainment and surveillance bias: patients flagged as genetically predisposed are likely under closer medical scrutiny, leading to earlier detection and more aggressive follow-up, which would inflate apparent survival independent of any underlying biology.

The limitations are substantial and the authors own them directly. They can't tell whether patients in the "no genetic susceptibility" arm simply never got tested, meaning some of them may actually carry unrecognized genetic risk and are misclassified into the wrong comparison group. TriNetX doesn't capture melanoma staging, so there's no ability to adjust for the single biggest melanoma prognostic variable there is — if genetically-flagged patients are systematically diagnosed at earlier stages, that alone could explain the entire survival difference, and propensity matching on demographics and comorbidities does nothing to correct for that gap. And residual confounding from anything unmeasured remains a live possibility in any database study like this, no matter how clean the matching looks on paper.

So where does this land practically? This is genuinely interesting and hypothesis-generating, but I would not call it practice-changing yet, specifically because of the missing staging data — that's too large a gap to draw firm prognostic conclusions for individual patient counseling. What it does usefully reinforce is the broader message that hereditary cancer predisposition in melanoma patients deserves recognition, both because it's apparently common and because it may carry downstream implications for surveillance intensity and family counseling. If you're not already routinely considering germline testing criteria in your melanoma patients with suggestive personal or family history, this is one more data point nudging in that direction — but treat the specific survival numbers here as provisional until someone replicates this with proper stage-adjusted, confirmed-genotype data.

That wraps the October review. To summarize the actionable versus the merely interesting: the barbed suture series offers concrete technique pearls on product choice and nerve-sensitive plication you can apply directly; the NLP-versus-ICD study won't change your clinic tomorrow but should change how you think about any outcomes research built on coded diagnoses; the Colorado sunscreen letter is a nice advocacy data point rather than a clinical signal; and the TriNetX melanoma genetics study is a thought-provoking but still-incomplete piece of the puzzle on hereditary predisposition and prognosis. Thanks for listening, and I'll see you next month.